Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.79)
# 580
Out of 5,182 analysts
222
Total ratings
54.96%
Success rate
6.84%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Reiterates: Overweight | $800 | $751.57 | +6.44% | 23 | Apr 23, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $45 → $54 | $58.71 | -8.02% | 17 | Apr 8, 2026 | |
| AMGN Amgen | Reiterates: Neutral | $350 | $344.55 | +1.58% | 20 | Apr 8, 2026 | |
| ABBV AbbVie | Maintains: Overweight | $250 → $240 | $198.71 | +20.78% | 19 | Apr 8, 2026 | |
| GILD Gilead Sciences | Maintains: Overweight | $135 → $155 | $130.40 | +18.87% | 17 | Feb 11, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $985 → $1,205 | $883.96 | +36.32% | 15 | Feb 5, 2026 | |
| PFE Pfizer | Reiterates: Neutral | $27 | $27.00 | - | 17 | Feb 4, 2026 | |
| MRK Merck & Co. | Maintains: Neutral | $116 → $120 | $111.90 | +7.24% | 12 | Feb 4, 2026 | |
| NUVL Nuvalent | Maintains: Overweight | $100 → $112 | $104.50 | +7.18% | 2 | Oct 31, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $485 | $430.29 | +12.71% | 4 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $59.49 | - | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $127.68 | +29.23% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $40.50 | -50.62% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $184.38 | -2.38% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $60 | $13.81 | +334.47% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $0.64 | +367.29% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.50 | +500.00% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $65.32 | +45.44% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $6.43 | +211.04% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $115.03 | -36.54% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $2.41 | +397.93% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $0.36 | +313.56% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $123.72 | +207.15% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $94.65 | -13.37% | 5 | Jan 16, 2019 |
Regeneron Pharmaceuticals
Apr 23, 2026
Reiterates: Overweight
Price Target: $800
Current: $751.57
Upside: +6.44%
Bristol-Myers Squibb Company
Apr 8, 2026
Maintains: Neutral
Price Target: $45 → $54
Current: $58.71
Upside: -8.02%
Amgen
Apr 8, 2026
Reiterates: Neutral
Price Target: $350
Current: $344.55
Upside: +1.58%
AbbVie
Apr 8, 2026
Maintains: Overweight
Price Target: $250 → $240
Current: $198.71
Upside: +20.78%
Gilead Sciences
Feb 11, 2026
Maintains: Overweight
Price Target: $135 → $155
Current: $130.40
Upside: +18.87%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $985 → $1,205
Current: $883.96
Upside: +36.32%
Pfizer
Feb 4, 2026
Reiterates: Neutral
Price Target: $27
Current: $27.00
Upside: -
Merck & Co.
Feb 4, 2026
Maintains: Neutral
Price Target: $116 → $120
Current: $111.90
Upside: +7.24%
Nuvalent
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $112
Current: $104.50
Upside: +7.18%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Overweight
Price Target: $535 → $485
Current: $430.29
Upside: +12.71%
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $59.49
Upside: -
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $127.68
Upside: +29.23%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $40.50
Upside: -50.62%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $184.38
Upside: -2.38%
Aug 14, 2024
Maintains: Overweight
Price Target: $200 → $60
Current: $13.81
Upside: +334.47%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $0.64
Upside: +367.29%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.50
Upside: +500.00%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $65.32
Upside: +45.44%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $6.43
Upside: +211.04%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $115.03
Upside: -36.54%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $2.41
Upside: +397.93%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $0.36
Upside: +313.56%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $123.72
Upside: +207.15%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $94.65
Upside: -13.37%